Bank of America Corp DE Makes New Investment in CeriBell (NASDAQ:CBLL)

Bank of America Corp DE acquired a new stake in CeriBell (NASDAQ:CBLL - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 19,256 shares of the company's stock, valued at approximately $498,000. Bank of America Corp DE owned approximately 0.05% of CeriBell at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of CBLL. Legal & General Group Plc acquired a new position in CeriBell during the fourth quarter valued at approximately $32,000. Summit Investment Advisors Inc. acquired a new stake in shares of CeriBell in the 4th quarter valued at approximately $33,000. Tower Research Capital LLC TRC bought a new position in shares of CeriBell in the fourth quarter valued at $37,000. BNP Paribas Financial Markets acquired a new position in CeriBell during the fourth quarter worth $43,000. Finally, PNC Financial Services Group Inc. acquired a new position in CeriBell during the fourth quarter worth $47,000.

CeriBell Stock Performance

Shares of NASDAQ CBLL traded up $0.08 during mid-day trading on Thursday, reaching $17.85. 19,764 shares of the company were exchanged, compared to its average volume of 278,028. The company's 50-day simple moving average is $16.53 and its 200-day simple moving average is $21.28. CeriBell has a twelve month low of $10.01 and a twelve month high of $32.75.

CeriBell (NASDAQ:CBLL - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.07. The company had revenue of $20.49 million during the quarter, compared to the consensus estimate of $19.30 million. On average, sell-side analysts anticipate that CeriBell will post -2.46 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have commented on CBLL shares. Canaccord Genuity Group reiterated a "buy" rating and issued a $33.00 price target on shares of CeriBell in a research note on Wednesday, February 26th. LADENBURG THALM/SH SH started coverage on shares of CeriBell in a research note on Friday, April 4th. They issued a "buy" rating and a $32.00 target price for the company. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, CeriBell has an average rating of "Buy" and an average target price of $32.50.

Insider Buying and Selling at CeriBell

In related news, CEO Xingjuan Chao sold 5,700 shares of the company's stock in a transaction dated Thursday, April 17th. The shares were sold at an average price of $15.02, for a total value of $85,614.00. Following the transaction, the chief executive officer now directly owns 746,451 shares in the company, valued at approximately $11,211,694.02. This represents a 0.76% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders have sold a total of 74,700 shares of company stock valued at $1,221,434 in the last ninety days. 20.10% of the stock is currently owned by corporate insiders.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.